Related Experiment Video
Updated: Jan 11, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC.
Matthew Lu1, Hayden Byrd2, Heidi Chen3
1Division of Hematology-Oncology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
JTO Clinical and Research Reports
|November 19, 2025
Summary
Tumor burden, measured as total body tumor volume (TV), predicts outcomes in relapsed small cell lung cancer (SCLC). Higher TV is linked to worse overall survival (OS) in these patients.
Area of Science:
- Oncology
- Medical Imaging
- Clinical Research
Background:
- Tumor burden predicts outcomes in limited-stage small cell lung cancer (SCLC).
- Data on tumor burden as a predictor in relapsed SCLC were previously lacking.
Purpose of the Study:
- To investigate if tumor burden predicts clinical outcomes in patients with relapsed SCLC.
Main Methods:
- Retrospective analysis of 93 relapsed SCLC patients.
- Calculated total body tumor volume (TV) at relapse.
- Used Cox proportional hazards model to assess TV's relationship with progression-free survival (PFS) and overall survival (OS).
Main Results:
- TV significantly predicted OS in relapsed SCLC patients, independent of other factors.
- Eastern Cooperative Oncology Group performance status and second-line therapy receipt also impacted OS.
Conclusions:
- Total body tumor volume (TV) is a significant predictor of overall survival (OS) in relapsed SCLC.
- Further research is needed to determine if initiating therapy at lower TV improves outcomes.
